Table 5.

Ongoing Studies in Relapsed/Refractory Paediatric Sarcoma

Clinical Trial Identifier	Name of Agent	Disease	Phase	Population	Primary Outcome
NCT02304458	Nivolumab ± Ipilimumab	Multiple solid tumours	I/II	1–18 years	Objective response rate
NCT02332668	Pembrolizumab	Relapsed or refractory solid tumours	II	6 months to 18 years	Objective response rate
NCT03041701	Ganitumab (anti- IGF1R) + Dasatinib (SRC inhibitor)	Relapsed or refractory rhabdomyosarcoma	I/II	No age limit	Objective response rate
NCT03709680	Palbociclib + Temozolomide + Irinotecan	Relapsed or refractory pediatric sarcomas	I/II	2–21 years	Objective response rate
NCT02095132	Adavosertib (WEE1 Inhibitor) + Irinotecan	Relapsed or refractory pediatric tumours	I/II	1–16 years	Maximal tolerable dose/toxicity
NCT02484443	Dinutuximab (Anti GD2) + Sargramostim	Recurrent osteosarcoma	II	Up to 16 years	Disease control rate
NCT02470091	Denosumab (RANKL inhibitor)	Osteosarcoma	II	11–50 years	Disease control rate
NCT03155620	Targeted Therapy Directed by Genetic Testing	Relapsed or refractory solid tumours	II	1–16 years	Objective response rate
NCT02867592	Cabozantinib	Relapsed or refractory solid tumours	II	<18 years	Objective response rate
NCT03514407	iNCB059872 (LSD1 Inhibitor)	Relapsed or refractory Ewing Sarcoma	Ib	12 years and older	Safety and preliminary antitumor activity
NCT02419417	BMS-986158 (BET Inhibitor) ± Nivolumab	Advanced solid tumours	I/IIa	12 years and older	Safety, tolerability, pharmacokinetics, pharmacodynamics
NCT03220347	INCB059872	Relapsed or refractory Ewing sarcoma	I	12 years and older	Safety, tolerability, pharmacokinetics, and pharmacodynamics